Health Care Consolidation Sparks Innovation, Takeda CEO Says Following Mega-Deal
*By Chloe Aiello*
Consolidation in the health care industry won't necessarily raise drug prices, Takeda CEO Christophe Weber told Cheddar, one week after the Japanese pharmaceutical company Takeda acquired Ireland-based drugmaker Shire for north of $50 billion.
"We spend around $4 billion per year in \[research and development\] and you need a lot of financial muscle for that. That is really what's behind the scale. You are looking for scale to finance R&D. The higher your productivity, the more flexible you will be on the pricing," Weber said.
The acquisition of Shire is the largest foreign buy-out ever executed by a Japanese firm, according to [The Economist](https://www.economist.com/business/2018/12/08/takedas-acquisition-of-shire-is-japans-biggest-ever-foreign-takeover), and makes Takeda one of the world's largest drug producers. The acquisition gives Takeda greater access to the U.S. market ー it listed on the New York Stock Exchange earlier this monthー as well as to a slate of new drugs in development. Post-merger, the new company is focusing on four different disease types ー gastroenterology, oncology, neuroscience, and rare disease ー and has 21 new drugs in late-stage development.
"It's exciting for us," Weber said.
Consolidation, especially in the expensive U.S. health care system, always invites scrutiny and concern over further hikes. Even political opposites like President Trump and Sen. Elizabeth Warren (D-Mass.) have slammed drug company executives for the high cost of drugs using similar language. Trump has accused pharmaceutical companies of ["getting away with murder"](https://www.reuters.com/article/us-usa-trump-drugpricing/trump-says-pharma-getting-away-with-murder-stocks-slide-idUSKBN14V24J), while Warren said they are "raking in profits on the backs of patients."
Weber acknowledged that competition is one key to price stabilization in health care, but said rather than contribute to price hikes, his new mega-company will leverage its size to finance research.
"The issue is R&D costs a fortune, and that's why medicines are expensive ー it's because R&D is so expensive. That's really the issue. So we need to work on better productivity, better R&D productivity. We have developed a unique R&D model, I believe, in the company and that's what will give us flexibility in the future," Weber said.
Weber said he sees a future role for technology and biotech companies in health care. They can contribute to innovations ー like gene therapy, for example ー and data collection.
"We need more real-life data, how is a patient doing instead of just clinical trial data, so this is where the tech can help to generate more of this data," Weber said.
For full interview [click here](https://cheddar.com/videos/takeda-ceo-vows-responsible-pricing-after-mega-pharmaceutical-merger).
President Donald Trump says he will allow Nvidia to sell its H200 computer chip used in the development of artificial intelligence to “approved customers” in China. Trump said Monday on his social media site that he had informed China’s leader Xi Jinping and “President Xi responded positively!” There had been concerns about allowing advanced computer chips into China as it could help them to compete against the U.S. in building out AI capabilities. But there has also been a desire to develop the AI ecosystem with American companies such as chipmaker Nvidia.
U.S. sports betting is booming as NFL and college football fuel massive activity. BetMGM CEO Adam Greenblatt breaks down trends, growth, and what’s next.
President Donald Trump says a deal struck by Netflix last week to buy Warner Bros. Discovery “could be a problem” because of the size of the combined market share. The Republican president says he will be involved in the decision about whether federal regulators should approve the deal. Trump commented Sunday when he was asked about the deal as he walked the red carpet at the Kennedy Center Honors. The $72 billion deal would bring together two of the biggest players in television and film and potentially reshape the entertainment industry.
Disney's changes to a program for disabled visitors are facing challenges in federal court and through a shareholder proposal. The Disability Access Service program, which allows disabled visitors to skip long lines, was overhauled last year. Disney now mostly limits the program to those with developmental disabilities like autism who have difficulty waiting in lines. The changes have sparked criticism from some disability advocates. A shareholder proposal submitted by disability advocates calls for an independent review of Disney's disability policies. Disney plans to block this proposal, claiming it's misleading. It's the latest struggle by Disney to accommodate disabled visitors while stopping past abuses by some theme park guests.
With a merger this big, creators, studios, and theaters all face uncertain futures. Here’s what experts are worried about and what good could come from it.
With disengagement rising and hybrid work shifting, 'Everybody Matters' author Bob Chapman explains why treating people well could define the future of work.
We sat down with Ali Furman, U.S. Consumer Markets Industry Leader at consulting firm PwC to ask what trends she garnered from the initial data this year.
